CF PharmTech says NMPA clears ICF001 trials in IPF, PPF

PUBT · 3d ago
CF PharmTech says NMPA clears ICF001 trials in IPF, PPF
  • CF PharmTech received NMPA implied clinical trial clearances for ICF001 in idiopathic pulmonary fibrosis, plus progressive pulmonary fibrosis.
  • The long-acting inhaled dry-powder candidate now has China trial clearance across four indications, including pulmonary arterial hypertension, plus PH-ILD.
  • The company plans Phase I studies in China, with potential overseas trials subject to additional regulatory clearances.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260824-12296695), on August 24, 2026, and is solely responsible for the information contained therein.